布格替尼治疗阿来替尼等TKI经治的日本ALK阳性NSCLC:J-ALTA二期试验结果
J-ALTA是一项日本单臂多中心开放标签二期试验,评估布格替尼在阿来替尼或其他ALK TKI耐药的晚期ALK阳性NSCLC患者中的疗效与安全性。72例入组患者中47例最近接受阿来替尼治疗,该人群IRC确认客观缓解率为34%(95%CI 21%-49%),中位缓解持续时间11.8个月,中位无进展生存期7.3个月。布格替尼对G1202R、I1171N、V1180L和L1196M继发突变显示抗肿瘤活性,安全性与此前广泛人群报告一致。
要点
- 阿来替尼耐药后布格替尼IRC确认ORR为34%,DCR为79%。
- 中位PFS 7.3个月,中位DOR 11.8个月。
- 对G1202R、I1171N、V1180L、L1196M继发突变有抗肿瘤活性。
核心结论
- 布格替尼在阿来替尼(含或不含既往克唑替尼)耐药的日本ALK阳性NSCLC患者中显示有临床意义的疗效。
研究设计与样本
- 单臂、多中心、开放标签二期试验,含安全性导入期及扩展期,入组日本患者。
- 扩展期纳入ALK TKI耐药或未接受过ALK TKI的患者,本文报告耐药人群结果。
- 给药方案为布格替尼180 mg每日一次,前7天导入期90 mg每日一次。
- 主要终点为独立评审委员会(IRC)按RECIST 1.1评估的确认客观缓解率。
主要发现
- 72例入组患者中47例最近接受的ALK TKI为阿来替尼(含或不含既往克唑替尼)。
- 分析截止时47例中14例仍在接受布格替尼治疗,中位随访12.4个月。
- 阿来替尼耐药人群IRC确认ORR为34%(95%CI 21%-49%),中位DOR为11.8个月(95%CI 5.5-16.4)。
- 疾病控制率为79%(95%CI 64%-89%),中位IRC评估PFS为7.3个月(95%CI 3.7-9.3)。
- 基线有可测量脑病灶的8例患者中2例确认颅内部分缓解。
关键数值与推荐
- 阿来替尼耐药人群IRC确认ORR:34%(95%CI 21%-49%)。
- 中位DOR:11.8个月(95%CI 5.5-16.4);DCR:79%(95%CI 64%-89%)。
- 中位IRC评估PFS:7.3个月(95%CI 3.7-9.3)。
临床怎么用
- 对于阿来替尼耐药的ALK阳性NSCLC日本患者,布格替尼180 mg(7天90 mg导入)可作为后续治疗选择。
- 继发突变G1202R、I1171N、V1180L、L1196M阳性者可能从布格替尼治疗中获益。
局限性
- 单臂设计,无对照。
- 仅纳入日本患者,外推需谨慎。
- 基线可测量脑病灶患者仅8例,颅内疗效数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This phase 2 trial evaluated the efficacy and safety of brigatinib in patients with advanced ALK-positive NSCLC refractory to alectinib or other ALK tyrosine kinase inhibitors (TKIs). METHODS: This single-arm, multicenter, open-label study in Japanese patients consisted of a safety lead-in followed by an expansion stage in patients refractory to ALK TKI or those naive for ALK TKI. Patients received brigatinib 180 mg once daily with 7-day lead-in at 90 mg once daily. Primary end point was independent review committee (IRC)-assessed confirmed objective response rate per the Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: We report the results of the lead-in and expansion in the patients refractory to ALK TKI. Of 72 patients enrolled, 47 had alectinib as most recent ALK TKI (with or without previous crizotinib). At analysis cutoff, 14 of the 47 remained on brigatinib (median follow-up: 12.4 mo). In the alectinib-refractory population, IRC-assessed confirmed objective response rate was 34% (95% confidence interval [CI]: 21%-49%) with median duration of response of 11.8 months (95% CI: 5.5-16.4). Disease control rate was 79% (95% CI: 64%-89%). Median IRC-assessed progression-free survival was 7.3 months (95% CI: 3.7-9.3). Two of eight patients with measurable brain lesions at baseline had confirmed intracranial partial response. Brigatinib has been found to have antitumor activity in patients with G1202R, I1171N, V1180L, and L1196M secondary mutations. The safety profile in Japanese patients was consistent with that in previous reports in broader populations. CONCLUSIONS: Brigatinib has been found to have clinically meaningful efficacy in Japanese patients with ALK+ NSCLC refractory to alectinib (with or without previous crizotinib).
引用
- Nishio M, Yoshida T, Kumagai T, et al. Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial. J Thorac Oncol. 2020. PMID: 33248320. doi:10.1016/j.jtho.2020.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。